The bill exempts pharmaceutical companies with two or more orphan drugs from Inflation Reduction Act price controls (previously it was one orphan drug), which is an unexpected last-minute legislative win that protects certain drug companies from price restrictions.
factualpending
Speaker
Dan CliftonEvidence Quote
“this bill says that if you have two orphan drugs, you will not be two or more, you will not be subject to inflation reduction act price controls”
Source
Big Beautiful Bill, Write-Off Revolution & Tariff Tempest — The Friday Market Wrap!— Steve EismanCreated: 8/11/2026, 4:52:42 AM
Your notes
Loading notes...